<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33564135</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5454</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Eye (London, England)</Title>
          <ISOAbbreviation>Eye (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data.</ArticleTitle>
        <Pagination>
          <StartPage>1305</StartPage>
          <EndPage>1316</EndPage>
          <MedlinePgn>1305-1316</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-020-01377-x</ELocationID>
        <Abstract>
          <AbstractText>The angopoietin/tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (Ang/Tie) pathway is an emerging key regulator in vascular development and maintenance. Its relevance to clinicians and basic scientists as a potential therapeutic target in retinal and choroidal vascular diseases is highlighted by recent preclinical and clinical evidence. The Ang/Tie pathway plays an important role in the regulation of vascular stability, in angiogenesis under physiological and pathological conditions, as well as in inflammation. Under physiological conditions, angiopoietin-1 (Ang-1) binds to and phosphorylates the Tie2 receptor, leading to downstream signalling that promotes cell survival and vascular stability. Angiopoietin-2 (Ang-2) is upregulated under pathological conditions and acts as a context-dependent agonist/antagonist of the Ang-1/Tie2 axis, causing vascular destabilisation and sensitising blood vessels to the effects of vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A synergistically drive vascular leakage, neovascularisation and inflammation, key components of retinal vascular diseases. Preclinical evidence suggests that modulating the Ang/Tie pathway restores vascular stabilisation and reduces inflammation. This review discusses how targeting the Ang/Tie pathway or applying Ang-2/VEGF-A combination therapy may be a valuable therapeutic strategy for restoring vascular stability and reducing inflammation in the treatment of retinal and choroidal vascular diseases.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Joussen</LastName>
            <ForeName>Antonia M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ricci</LastName>
            <ForeName>Federico</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, Tor Vergata University of Rome, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paris</LastName>
            <ForeName>Liliana P</ForeName>
            <Initials>LP</Initials>
            <Identifier Source="ORCID">0000-0002-9312-9924</Identifier>
            <AffiliationInfo>
              <Affiliation>F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Korn</LastName>
            <ForeName>Claudia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quezada-Ruiz</LastName>
            <ForeName>Carlos</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Genentech, Inc., South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Retina y Vitreo, Clinica de Ojos Garza Viejo, San Pedro Garza Garcia, Mexico.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zarbin</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-7811-7132</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, NJ, USA. zarbin@earthlink.net.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Eye (Lond)</MedlineTA>
        <NlmUniqueID>8703986</NlmUniqueID>
        <ISSNLinking>0950-222X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042682">Angiopoietins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D042787">Receptor, TIE-2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D042682" MajorTopicYN="Y">Angiopoietins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042787" MajorTopicYN="N">Receptor, TIE-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="Publisher" Language="chi">
        <AbstractText>摘要: 本篇文章是关于不同照明条件对原发性开角型青光眼 (POAG) 患者视力和生活质量影响的研究的系统回顾。研究对CINAHL, MEDLINE, PsycARTICLES, PsycINFO, Embase and Ovid Nursing Database六个数据库进行系统文献检索, 截止发表日期为2019年4月。检索内容包括诊断为POAG的患者, 在变换照明设备/光照水平或炫光的情况下评估人群的视功能和生活质量。两名研究者独立筛选符合标准的受试者。从实验设计, 入选者标准, 结果与结论中挑选合格的研究并提取数据。入选研究的质量经过了严格的评估。在8437项研究中, 共有56项研究符合入选标准。在POAG患者中调查光照对以下因素的影响: 生活质量 (18/56),心理物理学干预 (16/56), 功能性视力 (10/56), 日常活动 (10/56) 和定性发现 (2/56)。POAG会影响患者的低亮度对比敏感度, 炫光症状, 暗适应的时间和程度。在视觉生活质量调查问卷中, 根据POAG患者反馈, 照明设备, 炫光和暗适应的问题较其它问题更多见。这些问题随着进行性视野的缺失而严重, 与同年龄对照组相比(AMC), POAG患者在发病的早期在低亮度和不同亮度切换的环境中会面临更多的困难, 这对之前POAG患者早期阶段没有症状的认知进行了挑战。但是, 基于性能方面的研究很少显示POAG参与者和AMC在模拟非最佳照明条件下日常活动方面有显着差异。 需要对较大的样本进行进一步研究, 以优化环境照明和面向任务的照明, 以支持患者适应POAG。未来亟待大样本的研究为POAG患者提供优化环境和适合工作的照明。.</AbstractText>
      </OtherAbstract>
      <CoiStatement>AMJ is a consultant for Allergan, Bayer, Novartis and Roche, and has received research funding from Bayer and Novartis. FR is a consultant for Allergan, Bayer, Chengdu Kanghong, Iveric Bio, Formicon, Genentech/Roche, MS&amp;D and Novartis. LPP and CK are employees of F. Hoffmann-La Roche Ltd. CQR is an employee of Genentech, Inc., and holds stock options in Genentech, Inc. MZ is a consultant for Cell Cure, Chengdu Kanghong, Frequency Therapeutics, Genentech/Roche, Iduna, Iveric Bio, Life Biosciences, Novartis Pharma AG, NVasc, Ophthotech, Perfuse Therapeutics and Selphagy.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33564135</ArticleId>
        <ArticleId IdType="pmc">PMC8182896</ArticleId>
        <ArticleId IdType="doi">10.1038/s41433-020-01377-x</ArticleId>
        <ArticleId IdType="pii">10.1038/s41433-020-01377-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov. 2017;16:635–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28529319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26775688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4651818</ArticleId>
            <ArticleId IdType="pubmed">26113211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al.  HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30986442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti–vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4:19–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31324588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105:216–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7848066</ArticleId>
            <ArticleId IdType="pubmed">32265201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049445</ArticleId>
            <ArticleId IdType="pubmed">21593862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21925313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellström M, Phng L-K, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445:776–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17259973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, et al.  Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010;12:943–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20871601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011;12:551–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3319719</ArticleId>
            <ArticleId IdType="pubmed">21860391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korn C, Augustin HG. Mechanisms of vessel pruning and regression. Dev Cell. 2015;34:5–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26151903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10:165–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19234476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al.  Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118:149–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15260986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teichert M, Milde L, Holm A, Stanicek L, Gengenbacher N, Savant S, et al.  Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun. 2017;8:16106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5520106</ArticleId>
            <ArticleId IdType="pubmed">28719590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, et al.  Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest. 2016;126:3495–510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5004934</ArticleId>
            <ArticleId IdType="pubmed">27548530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone C, Piro G, Merz V, Simionato F, Santoro R, Zecchetto C, et al.  Angiopoietin-like proteins in angiogenesis, inflammation and cancer. Int J Mol Sci. 2018;19:431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5855653</ArticleId>
            <ArticleId IdType="pubmed">29389861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, et al.  Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012;122:1991–2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3366398</ArticleId>
            <ArticleId IdType="pubmed">22585576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hakanpaa L, Sipila T, Leppanen V-M, Gautam P, Nurmi H, Jacquemet G, et al.  Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nat Commun. 2015;6:5962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4316742</ArticleId>
            <ArticleId IdType="pubmed">25635707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor DS, Li F, et al.  Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem. 2000;275:9102–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10734041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBusk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res. 2004;298:167–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15242771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, et al.  Differential function of Tie2 at cell–cell contacts and cell–substratum contacts regulated by angiopoietin-1. Nat Cell Biol. 2008;10:513–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18425120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, et al.  Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) Genes Dev. 2004;18:1060–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC406295</ArticleId>
            <ArticleId IdType="pubmed">15132996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes DP, Marron MB, Brindle NP. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-κB inhibitor ABIN-2. Circ Res. 2003;92:630–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12609966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res. 2001;89:477–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11557733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>David S, Ghosh CC, Mukherjee A, Parikh SM. Angiopoietin-1 requires IQ domain GTPase-activating protein 1 to activate Rac1 and promote endothelial barrier defense. Arterioscler Thromb Vasc Biol. 2011;31:2643–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3249617</ArticleId>
            <ArticleId IdType="pubmed">21885850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, et al.  Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts. Nat Cell Biol. 2008;10:527–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18425119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammes H-P, Lin J, Wagner P, Feng Y, Vom Hagen F, Krzizok T, et al.  Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53:1104–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15047628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savant S, La Porta S, Budnik A, Busch K, Hu J, Tisch N, et al.  The orphan receptor Tie1 controls angiogenesis and vascular remodeling by differentially regulating Tie2 in tip and stalk cells. Cell Rep. 2015;12:1761–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6309948</ArticleId>
            <ArticleId IdType="pubmed">26344773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim M, Allen B, Korhonen EA, Nitschké M, Yang HW, Baluk P, et al.  Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J Clin Invest. 2016;126:3511–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5004955</ArticleId>
            <ArticleId IdType="pubmed">27548529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souma T, Thomson BR, Heinen S, Anna Carota I, Yamaguchi S, Onay T, et al.  Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP. Proc Natl Acad Sci U S A. 2018;115:1298–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5819405</ArticleId>
            <ArticleId IdType="pubmed">29358379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res. 2012;31:377–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3418965</ArticleId>
            <ArticleId IdType="pubmed">22580107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurihara T, Westenskow PD, Gantner ML, Usui Y, Schultz A, Bravo S, et al.  Hypoxia-induced metabolic stress in retinal pigment epithelial cells is sufficient to induce photoreceptor degeneration. Elife. 2016;5:e14319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4848091</ArticleId>
            <ArticleId IdType="pubmed">26978795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2:1117–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3411127</ArticleId>
            <ArticleId IdType="pubmed">22866203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deobhakta A, Chang LK. Inflammation in retinal vein occlusion. Int J Inflam. 2013;2013:438412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3638676</ArticleId>
            <ArticleId IdType="pubmed">23653882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato T, Takeuchi M, Karasawa Y, Takayama K, Enoki T. Comprehensive expression patterns of inflammatory cytokines in aqueous humor of patients with neovascular age-related macular degeneration. Sci Rep. 2019;9:19447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6923359</ArticleId>
            <ArticleId IdType="pubmed">31857597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19:942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5979417</ArticleId>
            <ArticleId IdType="pubmed">29565290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarbin MA, Casaroli-Marano RP, Rosenfeld PJ. Age-related macular degeneration: clinical findings, histopathology and imaging techniques. Dev Ophthalmol. 2014;53:1–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24732758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, et al.  Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103:2328–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1413680</ArticleId>
            <ArticleId IdType="pubmed">16452172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarks JP, Sarks SH, Killingsworth MC. Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye. 1997;11:515–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9425418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seddon JM, McLeod DS, Bhutto IA, Villalonga MB, Silver RE, Wenick AS, et al.  Histopathological insights into choroidal vascular loss in clinically documented cases of age-related macular degeneration. JAMA Ophthalmol. 2016;134:1272–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6014730</ArticleId>
            <ArticleId IdType="pubmed">27657855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116:S1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19800534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa K, Kannan R, Hinton DR. Molecular mechanisms of subretinal fibrosis in age-related macular degeneration. Exp Eye Res. 2016;142:19–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4568171</ArticleId>
            <ArticleId IdType="pubmed">25773985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, Hurd R, et al.  Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A–driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. Invest Ophthalmol Vis Sci. 2014;55:3709–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4059080</ArticleId>
            <ArticleId IdType="pubmed">24845632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Park D-Y, Park DY, Park I, Chang W, Nakaoka Y, et al.  Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest Ophthalmol Vis Sci. 2014;55:2191–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24609620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah RS, Soetikno BT, Lajko M, Fawzi AA. A mouse model for laser-induced choroidal neovascularization. J Vis Exp. 2015;106:e53502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4780856</ArticleId>
            <ArticleId IdType="pubmed">26779879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al.  Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5090659</ArticleId>
            <ArticleId IdType="pubmed">27742718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev. 2011;7:291–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21916837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yun J-H, Park SW, Kim JH, Park Y-J, Cho C-H, Kim JH. Angiopoietin 2 induces astrocyte apoptosis via αvβ5-integrin signaling in diabetic retinopathy. Cell Death Dis. 2016;7:e2101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5399183</ArticleId>
            <ArticleId IdType="pubmed">26890140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park SW, Yun J-H, Kim JH, Kim K-W, Cho C-H, Kim JH. Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy. Diabetes. 2014;63:3057–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24722242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee VK, Hosking BM, Holeniewska J, Kubala EC, Lundh von Leithner P, Gardner PJ, et al.  BTBR ob/ob mouse model of type 2 diabetes exhibits early loss of retinal function and retinal inflammation followed by late vascular changes. Diabetologia. 2018;61:2422–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6182653</ArticleId>
            <ArticleId IdType="pubmed">30094465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al.  Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA) Ophthalmologica. 2019;242:123–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31412332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khayat M, Lois N, Williams M, Stitt AW. Animal models of retinal vein occlusion. Invest Ophthalmol Vis Sci. 2017;58:6175–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29222552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3389193</ArticleId>
            <ArticleId IdType="pubmed">22555112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetic Retinopathy Clinical Research N, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al.  Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.e35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2937272</ArticleId>
            <ArticleId IdType="pubmed">20427088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123:1751–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4958614</ArticleId>
            <ArticleId IdType="pubmed">27156698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4877252</ArticleId>
            <ArticleId IdType="pubmed">26935357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorour OA, Liu K, Mehta N, Braun P, Gendelman I, Nassar E, et al.  Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema. Int J Retina Vitreous. 2020;6:17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7278067</ArticleId>
            <ArticleId IdType="pubmed">32523776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4898027</ArticleId>
            <ArticleId IdType="pubmed">27330279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Chui Ming GC, Tun SBB, et al.  Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2019;11:e10666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6505574</ArticleId>
            <ArticleId IdType="pubmed">31040127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, et al.  Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol. 2002;160:1683–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1850865</ArticleId>
            <ArticleId IdType="pubmed">12000720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, et al.  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014;124:4564–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4191011</ArticleId>
            <ArticleId IdType="pubmed">25180601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dewi NA, Aulanni’am A, Sujuti H, Widodo MA, Soeatmadji DW. Mechanism of retinal pericyte migration through angiopoietin/Tie-2 signaling pathway on diabetic rats. Int J Ophthalmol. 2018;11:375–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5861225</ArticleId>
            <ArticleId IdType="pubmed">29600169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfister F, Feng Y, vom Hagen F, Hoffmann S, Molema G, Hillebrands JL, et al.  Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes. 2008;57:2495–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2518502</ArticleId>
            <ArticleId IdType="pubmed">18559662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh H, Brindle NP, Zammit VA. High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. Microvasc Res. 2010;79:121–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20079751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert NG, Zhang X, Rai RR, Uehara H, Choi S, Carroll LS, et al.  Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. Exp Eye Res. 2016;145:248–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5862038</ArticleId>
            <ArticleId IdType="pubmed">26775053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nambu H, Nambu R, Oshima Y, Hackett SF, Okoye G, Wiegand S, et al.  Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier. Gene Ther. 2004;11:865–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15042118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Park JR, Choi J, Park I, Hwang Y, Bae H, et al.  Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. Sci Adv. 2019;5:eaau6732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6374104</ArticleId>
            <ArticleId IdType="pubmed">30788433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, et al.  Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res. 2013;19:6730–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24097868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Csaky K. Faricimab update. Presented at: Angiogenesis, Exudation, and Degeneration 2020; 9 Feb 2020; Miami, FL.</Citation>
        </Reference>
        <Reference>
          <Citation>Foxton RH, Uhles S, Grüner S, Revelant F, Ullmer C. Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization. EMBO Mol Med. 2019;11:e10204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6505683</ArticleId>
            <ArticleId IdType="pubmed">31040126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al.  Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16462802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholz A, Lang V, Henschler R, Czabanka M, Vajkoczy P, Chavakis E, et al.  Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin–dependent manner. Blood. 2011;118:5050–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21868579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, et al.  Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 2014;26:880–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25490450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benest AV, Kruse K, Savant S, Thomas M, Laib AM, Loos EK, et al.  Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One. 2013;8:e70459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3734283</ArticleId>
            <ArticleId IdType="pubmed">23940579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S-J, Lee C-K, Kang S, Park I, Kim YH, Kim SK, et al.  Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction. J Clin Invest. 2018;128:5018–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6205384</ArticleId>
            <ArticleId IdType="pubmed">30295643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Korhonen EA, Merlini A, Strauss J, Wihuri E, Nurmi H, et al.  Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. J Clin Invest. 2020;130:1977–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7108925</ArticleId>
            <ArticleId IdType="pubmed">32149735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M, et al.  Potential role of the angiopoietin/Tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:393–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12506101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jun J-I, Lau LF. Resolution of organ fibrosis. J Clin Invest. 2018;128:97–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5749507</ArticleId>
            <ArticleId IdType="pubmed">29293097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011) 2014;4:2–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4220516</ArticleId>
            <ArticleId IdType="pubmed">25401038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedlander M. Fibrosis and diseases of the eye. J Clin Invest. 2007;117:576–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1804382</ArticleId>
            <ArticleId IdType="pubmed">17332885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torricelli AA, Santhanam A, Wu J, Singh V, Wilson SE. The corneal fibrosis response to epithelial-stromal injury. Exp Eye Res. 2016;142:110–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4683352</ArticleId>
            <ArticleId IdType="pubmed">26675407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Koenig AL, Lavine KJ, Apte RS. Macrophage plasticity and function in the eye and heart. Trends Immunol. 2019;40:825–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6719788</ArticleId>
            <ArticleId IdType="pubmed">31422901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) Proc Natl Acad Sci U S A. 2002;99:8219–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC123048</ArticleId>
            <ArticleId IdType="pubmed">12048246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, et al.  Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest. 2011;121:2278–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3104773</ArticleId>
            <ArticleId IdType="pubmed">21606590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gemenetzi M, Lotery AJ, Patel PJ. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye. 2017;31:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5233933</ArticleId>
            <ArticleId IdType="pubmed">27716750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D. Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti-vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis. Retina. 2018;38:1276–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28723848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhrami-Gavazi E, Balaratnasingam C, Lee W, Freund KB. Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration. Int J Retina Vitreous. 2015;1:15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5088476</ArticleId>
            <ArticleId IdType="pubmed">27847608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Querques G, Srour M, Massamba N, Georges A, Ben Moussa N, Rafaeli O, et al.  Functional characterization and multimodal imaging of treatment-naive “quiescent” choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54:6886–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24084095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ophthotech’s Fovista fails third phase 3 trial in wet AMD. News release. Ophthotech: New York, NY, 2017. https://eyewire.news/articles/ophthotech-announces-results-from-third-phase-3-trial-of-fovista-in-wet-age-related-macular-degeneration/. Accessed 5 June 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Aerpio Pharmaceuticals announces results from TIME-2b study of AKB-9778 in diabetic retinopathy. News release. Aerpio Pharmaceuticals, Inc.: Cincinnati, OH, 2019. http://ir.aerpio.com/news-releases/news-release-details/aerpio-pharmaceuticals-announces-results-time-2b-study-akb-9778. Accessed 7 Aug 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Regeneron ends clinical program of Eylea and nesvacumab (Ang2 antibody) combination. News release. Regeneron Pharmaceuticals, Inc.: Tarrytown, NY, 2017. https://eyewire.news/articles/regeneron-provides-update-on-eylea-and-nesvacumab-ang2-antibody-combination-program/. Accessed 3 July 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, et al.  Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:964–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7489851</ArticleId>
            <ArticleId IdType="pubmed">32729897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B. Del Valle Rubido M, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:1–10..</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7393587</ArticleId>
            <ArticleId IdType="pubmed">32729888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aerpio Therapeutics reports positive clinical results from the phase 2a study of AKB-9778 in DME: the TIME-2 trial. News release. Aerpio Therapeutics, Inc.: Cincinnati, OH, 2016. https://eyewire.news/articles/aerpio-therapeutics-reports-positive-clinical-results-from-the-phase-2a-study-of-akb-9778-in-dme-the-time-2-trial/. Accessed 7 Aug 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY). https://clinicaltrials.gov/ct2/show/NCT02712008. Accessed 30 Mar 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). https://clinicaltrials.gov/ct2/show/NCT02713204. Accessed 30 Mar 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al.  Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30905643</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
